SK Biopharmaceuticals Co Ltd

326030.KS · Health Technology · Pharmaceuticals: Major · KR

skbp.com

About

SK Biopharmaceuticals Co Ltd is a leading bio-pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for central nervous system (CNS) disorders. The company is headquartered in South Korea and has been listed on the Korean Stock Exchange since 2014. The history of SK Biopharmaceuticals dates back to 1998 when it was established as a joint venture between SK Group and Hanmi Pharmaceutical. SK Biopharmaceuticals works closely with its parent companies, utilizing their extensive experience and infrastructure in research and development, production, and marketing. The business model of SK Biopharmaceuticals is based on creating value through research and development of drugs for the global market. Within this framework, the company develops innovative bio-pharmaceutical solutions for a range of therapeutic areas, particularly CNS disorders. SK Biopharmaceuticals strives to establish a strong presence in the global bio-pharmaceutical market through partnerships and strategic alliances with other companies. SK Biopharmaceuticals is organized into various divisions, including research and development, production, sales, and marketing. Each of these divisions is tailored to meet the needs of customers and patients to ensure optimal access to medications. The company has various products with different indications on the market worldwide, including the anticonvulsant Brivaracetam, which is approved for the treatment of epilepsy. Brivaracetam is a fast-acting, highly selective, and potent anticonvulsant that demonstrates significant reduction in seizure frequency in patients with epilepsy. SK Biopharmaceuticals continuously works to expand its product portfolio and develop innovative solutions for the treatment of neurological disorders. In addition to drug development for the global market, SK Biopharmaceuticals is also active in the field of biotechnology. The company is committed to harnessing the latest advancements in biotechnology and genomics to support the discovery, development, and commercialization of medications. SK Biopharmaceuticals has established itself as a leading company in the bio-pharmaceutical industry. The company is dedicated to excellence in research, development, and marketing of innovative solutions for the treatment of neurological disorders. With a strong global presence and a dedicated workforce, SK Biopharmaceuticals is well-positioned to further expand its position as a pioneer in the bio-pharmaceutical industry.

Annual results

Reported figures, KRW · revenue up 29.1% in 2025

YearRevenueNet incomeNet marginFree cash flow
2025707B267B37.8%—
2024548B241B44.0%—
2023355B-32.9B-9.3%—
2022246B-139B-56.6%—
2021419B64.8B15.5%—

326030.KS in MarketPulse

The live chart with RSI and moving averages, the price, news, signals and price alerts for SK Biopharmaceuticals Co Ltd are inside MarketPulse — currently in private beta.

Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.

SK Biopharmaceuticals Co Ltd (326030.KS) — company profile and financials · MarketPulse